Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TAK’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TAK’s TA Score shows that 3 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).
TAK (@Pharmaceuticals: Other) experienced а -3.09% price change this week, while ZTS (@Pharmaceuticals: Other) price change was -5.64% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.20%. For the same industry, the average monthly price growth was +34.49%, and the average quarterly price growth was +18755.45%.
TAK is expected to report earnings on Jul 31, 2024.
ZTS is expected to report earnings on Aug 01, 2024.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
TAK | ZTS | TAK / ZTS | |
Capitalization | 43.1B | 77.5B | 56% |
EBITDA | 1.01T | 3.67B | 27,660% |
Gain YTD | -7.779 | -22.843 | 34% |
P/E Ratio | 36.79 | 32.94 | 112% |
Revenue | 4.17T | 8.54B | 48,794% |
Total Cash | 317B | 2.04B | 15,547% |
Total Debt | 4.66T | 6.76B | 69,045% |
TAK | ZTS | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 51 | |
SMR RATING 1..100 | 87 | 19 | |
PRICE GROWTH RATING 1..100 | 78 | 64 | |
P/E GROWTH RATING 1..100 | 24 | 77 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (10) in the Pharmaceuticals Major industry is significantly better than the same rating for ZTS (82) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew significantly faster than ZTS’s over the last 12 months.
ZTS's Profit vs Risk Rating (51) in the Pharmaceuticals Generic industry is somewhat better than the same rating for TAK (100) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew somewhat faster than TAK’s over the last 12 months.
ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for TAK (87) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew significantly faster than TAK’s over the last 12 months.
ZTS's Price Growth Rating (64) in the Pharmaceuticals Generic industry is in the same range as TAK (78) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to TAK’s over the last 12 months.
TAK's P/E Growth Rating (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (77) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than ZTS’s over the last 12 months.
TAK | ZTS | |
---|---|---|
RSI ODDS (%) | 1 day ago49% | 2 days ago89% |
Stochastic ODDS (%) | 1 day ago38% | 2 days ago58% |
Momentum ODDS (%) | 1 day ago49% | N/A |
MACD ODDS (%) | N/A | 2 days ago59% |
TrendWeek ODDS (%) | 1 day ago50% | 2 days ago52% |
TrendMonth ODDS (%) | 1 day ago43% | 2 days ago53% |
Advances ODDS (%) | N/A | 22 days ago60% |
Declines ODDS (%) | 4 days ago45% | 4 days ago53% |
BollingerBands ODDS (%) | 1 day ago45% | 2 days ago71% |
Aroon ODDS (%) | 1 day ago34% | 2 days ago62% |
A.I.dvisor tells us that TAK and SNOA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TAK and SNOA's prices will move in lockstep.
Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
---|---|---|---|---|
TAK | 100% | +0.08% | ||
SNOA - TAK | 33% Poorly correlated | -6.84% | ||
RDY - TAK | 30% Poorly correlated | -0.56% | ||
OGI - TAK | 28% Poorly correlated | +2.19% | ||
CRON - TAK | 26% Poorly correlated | -0.41% | ||
ITCI - TAK | 26% Poorly correlated | -6.12% | ||
More |
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
---|---|---|---|---|
ZTS | 100% | -0.71% | ||
ELAN - ZTS | 46% Loosely correlated | -1.69% | ||
HLN - ZTS | 35% Loosely correlated | +0.12% | ||
SNDL - ZTS | 33% Loosely correlated | -7.58% | ||
PETQ - ZTS | 31% Poorly correlated | -1.67% | ||
EVO - ZTS | 31% Poorly correlated | +3.28% | ||
More |